Compare · NVO vs TRAW
NVO vs TRAW
Side-by-side comparison of Novo Nordisk A/S (NVO) and Traws Pharma Inc. (TRAW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TRAW operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 24222.5x TRAW ($8.9M).
- Over the past year, NVO is down 12.1% and TRAW is down 62.5% - NVO leads by 50.5 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 3 for TRAW).
- NVO has more recent analyst coverage (25 ratings vs 2 for TRAW).
- Company
- Novo Nordisk A/S
- Traws Pharma Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $8.9M
- 1M return
- -2.08%
- +2.89%
- 1Y return
- -12.07%
- -62.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest TRAW
- SEC Form 10-Q filed by Traws Pharma Inc.
- Traws Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
- Traws Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 4 filed by Chief Science Officer Virology Pauza Charles David
- SEC Form 4 filed by Director Cautreels Werner
- SEC Form 4 filed by Chief Operating Officer Savchuk Nikolay
- SEC Form 4 filed by Director Stover Jack E
- SEC Form 4 filed by Chief Executive Officer Dukes Iain D.
- SEC Form 4 filed by Chief Medical Officer Redfield Robert